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Abstract Integration of a DNA copy of the HIV-1 genome into
chromosomal DNA of infected cells is a key step of viral
replication. Integration is carried out by integrase, a viral protein
which binds to both ends of viral DNA and catalyses reactions of
the 3P-end processing and strand transfer. A 3P-3P branched
oligonucleotide functionalised by the intercalator oxazolopyr-
idocarbazole at each 5P-end was found to inhibit integration in
vitro. We show that both a specific (G,A) sequence and the OPC
intercalating agent contribute to the capability of the branched
oligonucleotide to form a parallel stranded structure responsible
for the inhibition.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Integration of a double-stranded DNA copy of the human
immunode¢ciency virus (HIV)-1 genome into chromosomal
DNA of newly infected cells is an essential step of the viral
replicative cycle. Integration is carried out by a viral pol-en-
coded protein, the integrase (IN). This enzyme has been
shown to be obligatory for HIV replication [1,2] and it has
no known cellular counterpart. IN is therefore an attractive
target for new selective anti-HIV therapies. Integrase directs
two distinct reactions: (1) the 3P-processing of the linear re-
verse-transcribed DNA, removing a dinucleotide from each
3P-end and (2) the strand transfer, a one step transesteri¢ca-
tion which involves the nucleophilic attack of an internucleo-
tidic phosphate of target DNA by the 3P-OH of the trimmed
3P-end, resulting in the covalent joining of donor into acceptor
DNA [3]. These two reactions can be mimicked in vitro by
using puri¢ed recombinant integrase [4] and oligonucleotide
substrates. Development of these in vitro assays made the
identi¢cation possible of several classes of integrase inhibitors
[5,6]. They can be classi¢ed into three major di¡erent groups.
The ¢rst group includes polyanionic compounds such as sur-
amin which bind to the positively charged C-terminal domain
of IN [7]. The second one gathers polyhydroxylated aromatic
compounds, most of them possessing a catechol function,
which bind to the catalytic domain of IN (for a review see
[2]). The third family comprises oligonucleotides which are the
most potent inhibitors in vitro identi¢ed to date [8]. Two types
of oligonucleotides inhibitors were reported: (1) tetrad form-
ing oligonucleotides [9,10] and (2) triplex forming oligonucleo-
tides (TFOs) [11,12]. Mechanisms of integration inhibition by
these oligonucleotides are distinct : TFOs inhibit integration
through the formation of a short triple helix on either U5 or
U3 viral DNA extremities whereas tetrad-forming oligonu-
cleotides exhibit a strong a⁄nity for integrase itself due to
their G-quadruplex structure. In both cases, IN binding to
its cognate sequence is prevented and integration is therefore
impaired.
In the present paper, we report the synthesis of a new bi-
functionalised oligonucleotide. This conjugate is a 3P-3P
branched oligonucleotide with both 5P-extremities substituted
by the oxazolopyridocarbazole (OPC) intercalating agent.
Evidence that it inhibits integrase in vitro is presented. More-
over, as shown by UV and circular dichroism (CD) studies,
this compound adopts a parallel duplex structure, which ap-
pears to be responsible for its speci¢c inhibitory properties.
Thus, parallel duplex forming oligonucleotides can be consid-
ered as a novel subgroup of the oligonucleotide family of
integrase inhibitors.
2. Materials and methods
2.1. Synthesis of 3P-3P-branched oligodeoxyribonucleotides
containing OPC
3P-3P-Branched oligonucleotides were synthesised on a modi¢ed
polymer support (Fig. 1). To produce this support the 5P-monome-
thoxytrityl derivative of thymidine triazolide (660 mg, 1 mmol) syn-
thesised as described in [13] was suspended with 4.5 g of CPG-500
polymer (100^200 mesh) in 30 ml of absolute pyridine and this mix-
ture was then evaporated to oil. The oil was dissolved in 10 ml of
absolute pyridine, then 2,4,6-triisopropylbenzenesulphonamide (1.5 g,
5 mmol) and N-methylimidazole (0.75 ml, 10 mmol) were added and
the reaction mixture was degassed and kept for 2 h. The polymer was
washed by acetonitrile (3 ml), treated with a 5% solution of 1-amino-
hexanol in acetonitrile for 10^15 min and then washed by 3 ml of
acetonitrile. The derivative containing the unprotected hydroxyl
function was blocked by the levulinyl protecting group. Loading of
the modi¢ed nucleoside residue into the polymer was at a rate of
30 Wmol/g.
The polymer (30 mg) was placed in a dismantled column to syn-
thesise 3P-3P branched oligonucleotides and the assembly began with
the synthesis of sequences: 5P-GGAAAA-3P-(T*) for (GA and GA-
OPC2) and 5P-AAGGAA-3P-(T*) for (cGA and cGA-OPC2), where
T* indicates the modi¢ed thymidine residue attached to the CPG
support (Fig. 1). After removal of the trityl group the column was
o¡-supported from the synthesiser, washed by anhydrous N,N-di-
methylformamide (DMF) (3U1 ml) and the 5P-hydroxyl was activated
by the treatment with a solution of 120 mg of bis-(N-succinimidyl)-
carbonate and 6 mg of 4-dimethylaminopyridine in 0.8 ml of anhy-
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drous DMF for 2 h. Then the polymer was washed by DMF (3U1
ml) and treated with a solution of 8 mg of amino containing OPC
derivative (OPC-NH2) prepared as previously described [14] in the
mixture of 0.4 ml of DMF, 0.2 ml of pyridine, 0.1 ml of water and
0.035 ml of triethylamine at 50‡C for 2 h. After this incubation the
polymer was washed by DMF (5U1 ml), methanol (5U1 ml) and
dried. The 5P-hydroxyl groups which did not react with OPC-NH2
were then acetylated. The levulinyl protecting group was removed
by treatment with 0.5 M hydrazine hydrate in pyridine/acetic acid
(4:1) (5 ml) for 15 min. The column was again inserted into the device
and synthesis of the second fragment of the oligonucleotides (GA-
OPC2 and cGA-OPC2) was carried out as during routine procedures.
After removal of the trityl group the column was o¡-supported from
the synthesiser and coupling of the second OPC group was carried out
as described above. After deprotection, the oligonucleotides were pu-
ri¢ed by RP HPLC in the acetonitrile gradient (0^40%) in 0.1 M
ammonium acetate containing 5% of methanol.
Precise sequences of compounds are described in Fig. 2. Concen-
trations of conjugates were determined spectrophotometrically; the
extinction coe⁄cients for GA-OPC2 and cGA-OPC2 (O260 = 237000
and 240300, respectively) and for GA and cGA (O260 = 117000 and
120300, respectively) were used.
2.2. Assays for integrase activity
Di¡erent assays were carried out to investigate the e¡ect of the
conjugates on integration in vitro: (1) 3P-end processing of a 21-bp
duplex, (2) strand transfer using a 21-bp duplex as both DNA sub-
strate and target, and (3) strand transfer of a 492-bp mini-viral DNA
into a plasmid target [15].
Sequences of the oligonucleotides (obtained from Eurogentec) used
as DNA substrates are described in Fig. 2. All oligonucleotides were
¢rst puri¢ed on a 18% polyacrylamide/7 M urea gel. Oligonucleotides
U5B, U3B, U5MB and U5B-2 were labelled at their 5P-end by T4
polynucleotide kinase (New England Biolabs) using [Q32P]ATP (sp.
act. 3000 Ci/mol NEN).
Two di¡erent integrase activities were assayed with the following
substrates:
(1) 3P-End processing. 21-mer duplexes U5B/A and U3B/A corre-
sponding to the sequences of U5 or U3 ends of the HIV-1 long
terminal repeats (LTR), respectively, were used as DNA substrates.
They were prepared by annealing 32P-labelled U5B, U5MB or U3B
with their complementary strand, respectively U5A, U5MA or U3A
in 100 mM NaCl and resulting duplexes were ¢nally desalted on a
ChromaSpin-10 column (Clontech).
(2) Strand transfer. (a) Homologous integration into a short duplex.
To assay only the strand transfer, a pre-processed substrate U5B-2/A
corresponding the viral U5 LTR end after 3P-end processing was used.
The 32P-labelled oligonucleotide U5B-2 was annealed to U5A and
desalted as described above. The same duplex represents both donor
and acceptor DNA. (b) Heterologous integration into a long DNA
fragment. A 492-bp U3U5 DNA which is generated by NdeI restric-
tion of the pU3U5 vector as previously described [15] was used as
donor substrate. Plasmid pSP70 was used as target DNA.
Recombinant integrase protein was a generous gift of Rho“ne-Pou-
lenc-Rorer and was puri¢ed as described [16]. The same reaction
conditions were used for both 3P-processing and strand transfer. Dif-
ferent amounts of oligonucleotides (GA, cGA, GA-OPC2, cGA-
OPC2) were incubated in 20 Wl with 0.3 pmol of the corresponding
32P-labelled DNA substrate in the presence of 1 pmol of integrase in
bu¡er containing 20 mM Tris, pH 7.5, 30 mM NaCl, 0.5 mM sper-
mine (Sigma), 10% glycerol, 10 mM DTT, 0.01% NP40, supplemented
with 8 mM MnCl2 and 2 mM MgCl2 at 30‡C. For heterologous
integration assay, 40 ng pSP70 vector was also added in the reaction
mixture. Reaction was stopped by adding 80 Wl of a stop solution
(0.3 M sodium acetate, pH 7.5) and the DNA fragments were
phenol-puri¢ed and precipitated with ethanol. For 3P-end processing
and homologous strand transfer, DNA fragments were suspended in
7 M urea and separated on a 18% polyacrylamide/7 M urea gel. For
heterologous strand transfer, DNA fragments were dissolved in 5%
glycerol and separated on a 1% agarose gel. Finally, gels were ana-
lysed on a STORM 840TM phosphorimager (Molecular Dynamics).
IC50 values were calculated with Image QuaNTTM 4.1 software.
2.3. Assay for integrase binding to its substrate
The same reaction mixtures prepared for integrase activity assay
were also used for the integrase binding assay. They were incubated
at 30‡C for 15 min, at room temperature for 15 more minutes and
¢nally incubated at 4‡C before being loaded on a 8% non-denaturat-
ing acrylamide gel containing 0.2% glycerol. Electrophoresis was per-
formed with a running bu¡er containing 50 mM Tris-Borate pH 7.5,
1 mM EDTA for 2 h at 4‡C (5.6 V/cm). Analysis and quanti¢cation
were performed on Molecular Dynamics STORM 840 phosphorimag-
er.
2.4. UV absorption spectroscopy
Thermal denaturation pro¢les were performed with 1.5 WM oligo-
nucleotide-OPC conjugates in 10 mM Tris-HCl bu¡er at pH 7.5,
10 mM MgCl2 and 2.5 mM spermine. Absorbance versus temperature
curves were recorded on a Uvikon 933 spectrophotometer. The tem-
perature of the bath was increased or decreased at a rate of 0.3‡C/min
from 8 to 68‡C by a Neslab RTE Bath/Circulator.
2.5. Circular dichroism (CD)
CD spectra were recorded on a modi¢ed dichrograph Mark V.
Samples were placed in a quartz cell (200 Wl, 1 mm path length)
thermostated at various temperatures. In typical experiments, 40 WM
of conjugates was dissolved in 20 mM Tris, pH 7,0 10 mM MgCl2,
2 mM MnCl2 and 2.5 mM spermine.
3. Results and discussion
3.1. Inhibition of HIV-1 Integration
Anti-integrase e¡ect of conjugates GA-OPC2, cGA-OPC2,
GA and cGA (see Fig. 2 for structures) were initially inves-
tigated in two di¡erent assays which measure the extent of 3P-
processing and strand transfer using either a blunt-ended 21-
mer duplex U5B/A or a 3P-processed duplex U5B-2/A, respec-
Fig. 1. Structure of CPG support containing a residue of modi¢ed
thymidine used to synthesise 3P-3P-branched oligonucleotides.
Fig. 2. Oligonucleotide-OPC conjugates and duplex target sequences.
U5B/A and U5B-2/A mimic the U5 LTR end, U3B/A the U3 LTR
and U5MB/A a mutated U5 LTR.
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tively. The 3P-processing reaction liberates the 3P-terminal di-
nucleotide, producing a 19-mer oligonucleotide (U5B-2) from
a 21-mer substrate (U5B). The strand transfer reaction is a
transesteri¢cation resulting in the insertion of one 3P-proc-
essed oligonucleotide into another oligonucleotide, yielding
higher molecular weight products with slower migration
than the 19-mer U5B-2 on acrylamide gel. As shown on
Fig. 3Aa (left) and Ba, the conjugate GA-OPC2 exhibited a
signi¢cant inhibition of both 3P-processing and strand transfer
with an IC50 of roughly 1.5WM. The same inhibition e⁄ciency
was also observed for the heterologous transfer of the 32P-
labelled 492-bp U3U5 DNA fragment into the plasmid
pSP70 (Fig. 3Bb). In sharp contrast, the oligonucleotide GA
alone without OPC inhibited neither 3P-processing (Fig. 3Aa,
right) nor strand transfer (data not shown). Moreover, the
control conjugate cGA-OPC2 having a di¡erent nucleotide
sequence did not show any inhibition either (Fig. 3Ab).
Thus, the inhibition e¡ect observed happens to be both se-
quence speci¢c and OPC dependent. It is worthy to note that
a similar inhibition e¡ect was observed when GA-OPC2 was
mixed with IN before or after addition of its substrate DNA.
3.2. Inhibition of integrase binding to its cognate substrate
To investigate the mechanism of inhibition further, we used
a gel shift approach to determine the in£uence of the conju-
gates on the binding of IN to its substrate. The complex of
integrase with its labelled substrate 32P-U5B/A remained on
the top of a 8% acrylamide gel running under non-denaturing
conditions whereas the non-bound substrate migrated much
faster (Fig. 3C). Increasing concentrations of conjugate GA-
OPC2 were incubated with integrase and 32P-U5B/A. The
amount of the 32P-labelled complex characterised by a slow
migration decreased as the concentration of the conjugate
increased (Fig. 3c). This result strongly suggests that the spe-
ci¢c conjugate GA-OPC2 prevented the integrase ¢xation to
its substrate. Conversely, the conjugate cGA-OPC2 that
showed no inhibitory activity, did not in£uence the integrase
binding (Fig. 3C). Finally, addition of the inactive, non-con-
jugated oligonucleotide GA at concentrations up to 20 WM
had no e¡ect on integrase-DNA complex formation either.
Altogether, these results indicate that the anti-integrase activ-
ity that was observed speci¢cally with GA-OPC2 can be as-
cribed to its capability of blocking IN binding to its DNA
substrate.
3.3. GA-OPC adopts a parallel stranded structure
Two di¡erent mechanisms have been previously summoned
to explain integrase inhibition by (G,A)- and (G,T)-containing
oligonucleotides : The ¢rst one involves formation of a short
triple-helix on the viral DNA extremity spanning over the
Fig. 3. Activity and binding assay of IN in presence of oligonucleotide-OPC conjugates. Corresponding concentrations are shown in WM. A:
3P-Processing assay on U5B/A target in the presence of GA-OPC2 and GA (a) or cGA-OPC2 and cGA (b). B: Strand transfer assay in the
presence of GA-OPC2 on U5B-2/A target (a) and on the long U3U5 fragment (b). C: Integrase binding on its target U5 in the presence of
GA-OPC2, cGA-OPC2 and GA.
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integrase binding site. This hypothesis was ¢rst considered
since a molecular modelling study suggested that the branched
oligonucleotide OPC-5P-GGAAAA3P-(CHOH)3-3P-AGAGA-
5P-OPC may form a thermodynamically stable triple helix
on the U5 sequence [17]. To address that possibility, GA-
OPC2 was assayed on the 3P-processing of either a mutated
LTR U5 extremity or the U3 DNA extremity (see Fig. 2). In
both cases, the substrate oligonucleotide did not contain a
sequence suitable for the triplex formation of this conjugate.
Inhibition e⁄ciency of GA-OPC2 with these substrates was
similar to the one found in the wild-type (wt) U5 sequence
(data not shown). Thus, the GA-OPC2 inhibitory activity
could not be a result of a triplex formation with the U5
DNA substrate. The second mechanism is based on the capa-
bility of G-rich oligonucleotides to form G-quadruplex con-
taining intra- or intermolecular structures. Because of their
strong a⁄nity for IN, these structured oligonucleotides pre-
vent the enzyme from binding to its substrate. In order to
detect a possible autostructure of GA-OPC, we carried out
thermal denaturation experiments at 295 nm. In fact, the var-
iation of temperature-dependent absorbance at this particular
wavelength is su⁄cient to monitor DNA structures involving
non-Watson-Crick bonds between guanine residues [18]. More
interestingly, this variation is inverted as compared with the
melting pro¢le at 260 nm of a classical duplex, thus allowing
the unambiguous identi¢cation of such structures. As shown
in Fig. 4, a temperature increase yielded a melting pro¢le for
GA-OPC2 with an absorbance decrease as high as 15%. The
Tm estimated from this pro¢le was 37.5‡C. In contrast, we did
not observe any melting transition at 295 nm with the three
other oligonucleotides which did not inhibit integration.
Therefore, the intrinsic autostructure of GA-OPC2 depends
both on sequence and intercalator OPC and appears to be
responsible for its inhibitory e¡ect.
Although it is widely known that G-rich oligonucleotides
can form G-quadruplex structures, alternating (G,A) oligonu-
cleotides were now shown to form preferentially parallel
stranded structures [19,20]. In order to solve the nature of
the autostructure unambiguously, CD studies were performed.
Under similar salt conditions as integration experiments, GA-
OPC2 displayed a CD spectrum with a strong positive Cotton
e¡ect at 265 nm and a negative one at 240 nm (Fig. 5, curve
1). The positive band is much stronger for GA-OPC2 than for
the three other compounds cGA-OPC2, GA and cGA. The
CD spectrum of GA-OPC2 corresponds to CD spectra ob-
served for parallel duplexes formed by alternating d(G-A)
sequences [21], [22]. Moreover, the notable absence of a pos-
itive CD peak at 295 nm shows that the structure does not
contain antiparallel G-quartets. Furthermore, while quartet
structures were observed in the presence of monovalent cati-
ons such as K or Na [23^25], these cations were not neces-
sary to detect the GA-OPC2 intermolecular structure. Finally,
when the GA-OPC2 conjugate was heated to 65‡C, the max-
imum amplitude of its spectrum decreased and the positive
band shifted from 265 to 270 nm (Fig. 5, curve 2) whereas
cGA exhibits a maximum amplitude at 265 nm, which re-
mained unchanged after heating (Fig. 5, curve 3 and 4). In
agreement with the absence of autostructure of cGA-OPC2
and GA, their respective spectra were not temperature de-
pendent either (data not shown).
Thus, taken together, CD and UV-absorption experiments
results provide a compelling evidence for the presence of an
autostructure, relevant to the anti-integrase activity observed
with GA-OPC2, and strongly suggest the involvement of a
parallel stranded duplex, stable at neutral pH and 10 mM
MgCl2. Both the intercalating agent OPC and a speci¢c se-
quence are required for autostructure formation. OPC re-
quirement is in good agreement with the previous report of
a stabilisation of autostructure formed by 5P-end substituted
d(TGGGAG) oligonucleotides [26].
Finally, to reinforce the correlation between the GA-OPC2
structure and its inhibitory activity, integration experiments
were carried out at a di¡erent temperature. Since a Tm of
37.5‡C was obtained from melting experiments, a decrease
of the inhibition e⁄ciency should occur when the reaction
temperature increased. When the integration assay was per-
formed at 37‡C instead of 30‡C, we readily observed a de-
crease of the conjugate e⁄ciency since IC50 shifted from 1.5 to
5 WM. This result brings new evidence that the e⁄ciency of
integrase inhibition was dependent on the oligonucleotide
autostructure.
In conclusion, speci¢c inhibition of HIV-1 integrase by GA-
OPC2 versus controls led us to the conclusion that integrase is
able to interact with parallel structured oligonucleotides. To
our knowledge, this is the ¢rst report of an oligonucleotide
capable to inhibit integrase by such a mechanism.
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